NASDAQ · THAR
Tharimmune, Inc.
$4.74 +$0.26 (+5.80%) 1D
Tharimmune, Inc.
Key Metrics
$90.77M
Market cap
—
P/E · TTM
—
Revenue · TTM
—
Net income
EPS · TTM
—
Dividend yield
—
Free cash flow
—
Beta · 1Y
1.99
EBITDA · TTM
—
Gross margin
—
Snapshot
Market cap$90.77M
Enterprise value—
Shares outstanding35.0M
52-wk range$1.08 – $9.08
Avg volume · 20D1.4M
Net cash
—
Book value / share—
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Tharimmune, Inc.
IPO dateJan 12, 2022
Employees3
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.
Wolf Grade COMING SOON
—
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.
Valuation
P/E—
P/S—
P/FCF—
EV/EBITDA—
EV/Sales—
Graham №—
Profitability
Gross
—
Operating
—
Net
—
FCF
—
ROE / ROIC
— · —
Financial Health
Current ratio—
Quick ratio—
Debt / equity—
Debt / EBITDA
—
Net cash
—
Working capital—
Cash Flow · TTM
Operating CF
—
Capex
—
Free cash flow
—
Buybacks
—
Dividends paid
—
Shareholder yield
—
Piotroski F-Score
—
Needs two fiscal years of filings
Altman Z-Score
—
Insufficient balance-sheet inputs
Graham Number vs Price
—
Requires positive earnings and book value